{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-221586","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2023-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.335425+00:00","generated_at":"2026-06-11T03:37:03.021985+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Design Therapeutics CEO Siffert resigns; Chair Shah appointed CEO, receives stock options","bullets":["João Siffert resigned as President/CEO/principal financial officer effective Aug 25, 2023; employee status ends Sept 1, 2023.","Pratik Shah, Ph.D., Board Chair, appointed President, CEO and principal financial officer effective Aug 25, 2023; Simeon George named lead independent director.","Siffert receives 12-month salary continuation, $230,220 prorated bonus, 12-month COBRA, extended option exercisability (6 months).","Shah granted options: 1,050,000 shares time-vesting; 525,000 shares contingent on FA IND clearance; 525,000 shares contingent on FA Phase 2a start."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-221586","json":"https://secwatch.observer/filing/0001193125-23-221586.json","markdown":"https://secwatch.observer/filing/0001193125-23-221586.md","text":"https://secwatch.observer/filing/0001193125-23-221586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/0001193125-23-221586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/d530547d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T03:37:03.021985+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33f088af7c","claim":"João Siffert resigned as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..","evidence_excerpt":"agreed to the resignation of Dr. Siffert from all offices of the Company and from the Board, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/0001193125-23-221586-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President, Chief Executive Officer and principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"4fa65541e6","claim":"Pratik Shah was appointed as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..","evidence_excerpt":"On August 25, 2023, the Board appointed Pratik Shah, Ph.D., as the Company’s President, Chief Executive Officer and principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/0001193125-23-221586-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Executive Officer and principal financial officer"}],"fact_type":"executive_change"},{"claim_id":"da77e5117d","claim":"Simeon George was appointed as Lead Independent Director at Design Therapeutics, Inc..","evidence_excerpt":"the Board appointed Simeon George, M.D., as the Company’s lead independent director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312523221586/0001193125-23-221586-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}